De novo mutation in 2 patients with neonatal-onset epilepsy by Guella, Ilaria et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
De novo mutation in 2 patients with neonatal-onset epilepsy
Guella, Ilaria; Huh, Linda; McKenzie, Marna B; Toyota, Eric B; Bebin, E Martina; Thompson, Michelle
L; Cooper, Gregory M; Evans, Daniel M; Buerki, Sarah E; Adam, Shelin; Van Allen, Margot I; Nelson,
Tanya N; Connolly, Mary B; Farrer, Matthew J; Demos, Michelle
Abstract: OBJECTIVE We describe 2 additional patients with early-onset epilepsy with a de novo mu-
tation. METHODS Whole-exome sequencing was performed in 2 unrelated patients with early-onset
epilepsy and their unaffected parents. Genetic variants were assessed by comparative trio analysis. Clin-
ical evolution, EEG, and neuroimaging are described. The phenotype and response to treatment was
reviewed and compared to affected siblings in the original report. RESULTS We identified the same de
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De novo FGF12 mutation in 2 patients
with neonatal-onset epilepsy
ABSTRACT
Objective: We describe 2 additional patients with early-onset epilepsy with a de novo FGF12
mutation.
Methods: Whole-exome sequencing was performed in 2 unrelated patients with early-onset epi-
lepsy and their unaffected parents. Genetic variants were assessed by comparative trio analysis.
Clinical evolution, EEG, and neuroimaging are described. The phenotype and response to treat-
ment was reviewed and compared to affected siblings in the original report.
Results: We identified the same FGF12 de novo mutation reported previously (c.G155A, p.R52H)
in 2 additional patients with early-onset epilepsy. Similar to the original brothers described, both
presented with tonic seizures in the first month of life. In the first patient, seizures responded to
sodium channel blockers and her development was normal at 11 months. Patient 2 is a 15-year-
old girl with treatment-resistant focal epilepsy, moderate intellectual disability, and autism. Car-
bamazepine (sodium channel blocker) was tried later in her course but not continued due to an
allergic reaction.
Conclusions: The identification of a recurrent de novo mutation in 2 additional unrelated probands
with early-onset epilepsy supports the role of FGF12 p.R52H in disease pathogenesis. Affected
carriers presented with similar early clinical phenotypes; however, this report expands the phe-
notype associated with this mutation which contrasts with the progressive course and early
mortality of the siblings in the original report. Neurol Genet 2016;2:e120; doi: 10.1212/
NXG.0000000000000120
GLOSSARY
EOEE 5 early-onset epileptic encephalopathy; WES 5 whole-exome sequencing.
High-throughput sequencing technology, including whole-exome sequencing (WES), has rev-
olutionized gene discovery in epilepsy. It has also demonstrated the significant genetic hetero-
geneity of epilepsy and the importance of de novo mutations in the epileptic encephalopathies,1
which are the most severe forms of epilepsy. Recently, WES in a family quintet with 2 affected
siblings with early-onset epileptic encephalopathy (EOEE) and cerebellar atrophy identified
fibroblast growth factor 12 (FGF12, also known as FHF1) as a putative gene responsible.2 A
de novo gain-of-function variant (p.R52H) was found in 2 affected siblings with lethal disease.
FGF12 encodes a cytosolic protein that interacts with neuronal sodium channels and increases
their voltage-dependent fast inactivation.3 Here, we performed WES-trio analysis and identified
the same de novo missense mutation in 2 patients with severe neonatal-onset epilepsy and
variable clinical outcomes.
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METHODS Standard protocol approvals, registrations,
and patient consents. This study was approved by site-specific
Institutional Review Boards, and informed consent was obtained
from all individuals.
Genetic analysis. Peripheral blood samples were collected from
the proband and her parents. Genomic DNA was extracted from
peripheral blood lymphocytes following standard protocols.
Patient 1 exonic regions were captured using the Ion AmpliSeq
Exome Kit (57.7 Mb), and WES was performed on the Ion Pro-
ton System according to manufacturers’ recommendations (Life
Technologies, Carlsbad, CA). Candidate variants were validated
by Sanger sequencing as previously described.4 Primer sequences
and PCR conditions are available on request. Patient 2 was iden-
tified through GeneMatcher (genematcher.org/).5 WES and data
analysis were performed as part of a trio-based clinical sequencing
study at HudsonAlpha. Exome capture was completed using
Nimblegen SeqCap EZ Exome v3 (Roche, Basel, Switzerland),
and sequencing was conducted on the Illumina HiSeq 2000
(Illumina, San Diego, CA). Sanger confirmation of variants,
including confirmation of absence from both biological parents,
was performed by a College of American Pathologists/Clinical
Laboratory Improvement Amendments–certified or Diagnostic
Accreditation Program–accredited diagnostic laboratory.
RESULTS Family trio analysis identified the same
FGF12 missense mutation in both patients, identical
to the variant reported previously.2 The mutation is
a de novo heterozygous G.A transition at position
155 of the complementary DNA (NM_004113)
which results in a p.R52H missense substitution.
Sanger sequencing was performed in both trios and
confirmed that the mutation was only present in the
affected probands. No other pathogenic mutations in
known epilepsy genes were present.
Clinical phenotypes. Patient 1 is a developmentally nor-
mal 11-month-old baby, born at term after an
uncomplicated pregnancy. She presented on day 3 of
life with a 2-minute seizure involving extension of all
limbs, head, and eye deviation to the right side and
apnea with desaturation. On day 3, the interictal
EEG showed multifocal spikes. During continuous
video-EEG monitoring on day 8, multiple
independent left and right frontal seizures were
recorded. Seizures occurred from sleep, and 1 typical
seizure with corresponding EEG is shown in the
video at Neurology.org/ng and in the figure. Seizures
continued despite treatment with phenobarbital,
levetiracetam, topiramate, and a midazolam infusion.
She required intubation and ventilation for 3 days. Her
seizures stopped on day 20 of age after the addition of
phenytoin. She had 1–3 seizures per month
on phenytoin and topiramate. Carbamazepine was
added to topiramate at 6 weeks of age, and she has
been seizure free since 5 months of age on
carbamazepine (30 mg/kg/d). Her initial neurologic
examination showed mild hypotonia which later
resolved. Her development remains normal. Her
head circumference remains at the 85th percentile,
and her EEG performed at 10 months of age was
normal. Extensive neurometabolic investigations and
a head MRI performed at day 4 of life were
unremarkable.
Patient 2 is a 15-year-old girl, born at term fol-
lowing an uncomplicated pregnancy and delivery.
She presented on day 2 of life with tonic seizures
characterized by generalized stiffening which
evolved to intermittent stiffening and twitching of
the limbs. On day 11, her EEG demonstrated sup-
pression of the background and multifocal spikes.
Seizures did not respond to phenobarbital, clonaze-
pam, topiramate, and lamotrigine. At 4 years of age,
she developed focal seizures with impaired awareness
which could evolve to bilateral tonic-clonic seizures.
The interictal EEG showed mild background slow-
ing and left frontotemporal spikes. Carbamazepine
was tried at 4 years of age; however, it was stopped
immediately following an allergic reaction. Rufina-
mide was added to lamotrigine at the age of 8 years
and at most recent follow-up, the patient has been
seizure free for 1 year. Developmental delay was
noted by 1 year of age, and her development re-
gressed at times of increased seizure frequency. She
currently has moderate intellectual disability and
autism. MRI of the brain at 2 weeks and 2 years
of age was normal except for an incidental Chiari I
malformation.
DISCUSSION In this report, we describe 2 addi-
tional patients with a de novo p.R52H mutation
in FGF12 but with milder phenotypes. The same
variant observed in our patients was recently
described in 2 siblings with a lethal disorder char-
acterized by EOEE and cerebellar atrophy.2 All 4
affected individuals presented with early-onset tonic
seizures and most had seizures from sleep (table).
Patient 1 does not have an epileptic encephalopathy
given the cessation of seizures, normal development,
and normal EEG. However, patient 2 and the
original reported clinical features of the siblings2
are consistent with an epileptic encephalopathy. In
all cases, seizures were refractory to multiple
antiseizure medications. However, patient 1 had
a good response to sodium channel blockers and
has been seizure free since 5 months of age. In
patient 2, carbamazepine resulted in an allergic
reaction and phenytoin was not tried. Patient 2
is currently seizure free on a combination of
lamotrigine and rufinamide, which is possibly due
to the effects of these drugs on the sodium
channel. The current neurologic examination and
development are normal for patient 1. This
contrasts with the report of the siblings, which
indicates a neurodegenerative course associated
with early death. The clinical course of patient 2
2 Neurology: Genetics
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Figure Patient 1: Ictal EEG
Seizure began with arousal from sleep and extension of all 4 limbs followed by clonic jerking of the right arm and bradycardia
(see video). Ictal EEG demonstrated (A) generalized attenuation of EEG activity at seizure onset, followed by rhythmic
spikes in left central area; (B) spread to right central area; (C) spread to bilateral central frontal parietal regions; and (D) pos-
tictal suppression.
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also is not as severe as that of the siblings; however,
her seizures were refractory to treatment except for
the past year, and she did have developmental
regression associated with increased seizure
activity. She also has intellectual disability and
autism. In the original report,2 progressive
cerebellar atrophy was also a prominent feature of
the disease phenotype which differs from the
normal MRI seen in patient 1 and the incidental
Chiari I malformation identified on MRI in patient
2. It is difficult to accurately compare MRI findings
given the young age of patient 1; however, MRI of
patient 2 showed no sign of cerebellar atrophy at age
2. The milder phenotype with normal clinical
outcome seen in patient 1 may be influenced by
the early seizure control. However, other genetic
and/or environmental factors may also be playing
a role. Although the young age of patient 1 limits
a clear impression of the natural history of this
disorder, there is a striking clinical difference
between patient 1 normal clinical course to date
and moderate to severe course of patient 2 and
the lethal outcome of the previously described
siblings. Early seizure control in patient 1 suggests
Table Clinical features of patients with de novo p.R52H FGF12 mutation
Individuals Patient 1 (this study) Patient 2 (this study) Patient 12 Patient 22
Sex Female Female Female Male
Seizure onset 3 d 2 d 14 d 28 d
Age or age at deatha 11 mo 15 y 7 ya (status epilepticus) 3.5 ya (unknown cause)
Gestational age Term Term Term (twin fetus died in utero) NA
Diagnosis Early-onset tonic and
focal seizures
EOEE EOEE with cerebellar atrophy EOEE with cerebellar atrophy
Development prior to
seizure onset
Normal Normal Normal Normal
Seizure type at onset Tonic Tonic Tonic Tonic
Course of seizures Focal motor seizures; last
seizure at 5 mo
Focal with impaired
awareness, evolution to
generalized tonic-clonic;
seizure free for 1 y
Tonic, generalized, and focal Tonic, generalized, and focal
Ictal EEG Generalized suppression, then
rhythmic spikes in the left, then
right central region
Generalized spike
wave followed by
diffuse depression or
electrodecremental events
Low voltage fast activity,
followed by long suppression
of background
Low voltage fast activity, followed
by long suppression of background
Interictal Multifocal spikes then normal Suppression of background
and multifocal spikes,
mild background
slowing, and left
frontotemporal spikes
Background slowing, multifocal
epileptic abnormalities, and later
hypsarrhythmia
Background slowing, multifocal
epileptic abnormalities, and later
hypsarrhythmia
Timing of seizure
occurrence
Sleep Waking and sleep Usually during sleep Usually during sleep
Head circumference Normal Normal Acquired microcephaly Acquired microcephaly
Neurologic findings Hypotonia which resolved Normal Axial hypotonia, ataxia (limbs),
severe feeding difficulties
Hypotonia, ataxia, severe feeding
difficulties
Response to treatment Responded to phenytoin and
carbamazepine. Failed
phenobarbital, levetiracetam,
topiramate, and
midazolam infusion
Seizure reduction on
rufinamide
and lamotrigine. Failed
phenobarbital, clonazepam,
and topiramate; rash
on carbamazepine
Treatment resistant Treatment resistant
ID Normal Moderate Profound Profound
Development Normal Speech delay (20 words
at 5 y), ambulatory,
sensory issues, autism
Sit without support (24 mo), no
walking or standing, no speech
NA
Visual abnormalities None Nystagmus, intermittent
esotropia, moderately
farsighted and wears
corrective lenses
Cortical visual impairment Poor visual contact
Funduscopy Normal Normal Normal initially, pale optic discs
and narrow vessels at 5 y
NA
MRI (age) Normal (4 d) Normal (2 wk), Chiari I
malformation (2 y)
Normal (5 mo), cerebellar
atrophy (6 y)
Normal (2 mo), cerebellar atrophy
(3 y)
Abbreviations: EOEE 5 early-onset epileptic encephalopathy; ID 5 intellectual disability; NA 5 not available.
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possible important treatment implications for this
genetic disorder which could affect outcome.
During the preparation of this manuscript, we
became aware of 3 additional patients with an epilep-
tic encephalopathy carrying the same FGF12 de novo
mutation.6 The identification of a recurrent de novo
mutation in 6 unrelated patients all presenting with
early-onset epilepsy strongly supports the involve-
ment of FGF12 in disease pathogenesis.7,8 Moreover,
the identification of additional patients carrying the
same FGF12 variant broadens the phenotypic spec-
trum associated with this gene.
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